ReviewClinical immunology (Orlando, Fla.)2018
The serine/threonine protein phosphatase 2A controls autoimmunity.
Review in Clinical immunology (Orlando, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Protein phosphatase 2A orchestrates hematopoietic fate determination via modulation of lactate metabolism.Haematologica · 2026Article
- The role of epigenetic regulation in cuproptosis, ferroptosis and NETosis in the pathogenesis of autoimmune diseases.Apoptosis : an international journal on programmed cell death · 2025Review
- An atlas of single-cell eQTLs dissects autoimmune disease genes and identifies novel drug classes for treatment.Cell genomics · 2025Article
- Functional Role of Protein Phosphatase-6 (Current medicinal chemistry · 2025Review
- Metabolic regulation of the immune system in health and diseases: mechanisms and interventions.Signal transduction and targeted therapy · 2024Review
- Rare genetic variants provide a mechanistic basis for immune imbalance in IgG4-related disease.The Journal of clinical investigation · 2024Article
- Psoriasis and Lupus Erythematosus-Similarities and Differences between Two Autoimmune Diseases.Journal of clinical medicine · 2024Review
- IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease.The Journal of clinical investigation · 2024Article
- Putting a Novel Emphysema Treatment on the SMAP.American journal of respiratory cell and molecular biology · 2023Article
- "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".Genes and immunity · 2023Review
- Article
- Protein Phosphatase 2A: Role in T Cells and Diseases.Journal of immunology research · 2023Review
- Amino Acid Profiles and Nutritional Evaluation of Fresh Sweet-Waxy Corn from Three Different Regions of China.Nutrients · 2022Article
- Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.Signal transduction and targeted therapy · 2022Review
- Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.Clinical reviews in allergy & immunology · 2022Review
- T Cells, Interleukin-2 and Systemic Lupus Erythematosus-From Pathophysiology to Therapy.Cells · 2022Review
- High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.Journal of Cancer · 2022Article
- Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies.Molecules (Basel, Switzerland) · 2021Review
- PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity.Frontiers in immunology · 2021Review
- Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells.Current research in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Protein phosphatase 2A (PP2A) is the first serine/threonine phosphatase recognized to contribute to human and murine lupus immunopathology. PP2A expression in SLE is controlled both epigenetically and genetically, and it is increased in patients with SLE, which contributes to decreased IL-2 production, decreased CD3ζ and increased FcRγ expression on the surface of T cells, increased CREMα expression, hypomethylation of genes associated with SLE pathogenesis, and increased IL-17 production. β regulatory subunit of PP2A regulates IL-2 deprivation-induced T cell death and is decreased in SLE patients. A mouse overexpressing PP2A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.